1. Home
  2. MBX vs SAR Comparison

MBX vs SAR Comparison

Compare MBX & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBX
  • SAR
  • Stock Information
  • Founded
  • MBX 2018
  • SAR 2007
  • Country
  • MBX United States
  • SAR United States
  • Employees
  • MBX N/A
  • SAR N/A
  • Industry
  • MBX
  • SAR Investment Managers
  • Sector
  • MBX
  • SAR Finance
  • Exchange
  • MBX NYSE
  • SAR Nasdaq
  • Market Cap
  • MBX 347.9M
  • SAR 346.8M
  • IPO Year
  • MBX 2024
  • SAR 2007
  • Fundamental
  • Price
  • MBX $6.97
  • SAR $25.30
  • Analyst Decision
  • MBX Strong Buy
  • SAR Buy
  • Analyst Count
  • MBX 4
  • SAR 4
  • Target Price
  • MBX $37.25
  • SAR $25.08
  • AVG Volume (30 Days)
  • MBX 223.9K
  • SAR 95.5K
  • Earning Date
  • MBX 03-17-2025
  • SAR 05-05-2025
  • Dividend Yield
  • MBX N/A
  • SAR 13.14%
  • EPS Growth
  • MBX N/A
  • SAR 33.28
  • EPS
  • MBX N/A
  • SAR 2.49
  • Revenue
  • MBX N/A
  • SAR $154,793,533.00
  • Revenue This Year
  • MBX N/A
  • SAR $6.07
  • Revenue Next Year
  • MBX N/A
  • SAR N/A
  • P/E Ratio
  • MBX N/A
  • SAR $10.16
  • Revenue Growth
  • MBX N/A
  • SAR 11.52
  • 52 Week Low
  • MBX $6.67
  • SAR $21.56
  • 52 Week High
  • MBX $27.50
  • SAR $26.49
  • Technical
  • Relative Strength Index (RSI)
  • MBX N/A
  • SAR 58.94
  • Support Level
  • MBX N/A
  • SAR $24.82
  • Resistance Level
  • MBX N/A
  • SAR $25.58
  • Average True Range (ATR)
  • MBX 0.00
  • SAR 0.36
  • MACD
  • MBX 0.00
  • SAR 0.15
  • Stochastic Oscillator
  • MBX 0.00
  • SAR 86.73

About MBX MBX BIOSCIENCES INC

MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

Share on Social Networks: